In this phase 1/2a trial, the Ad26.RSV.preF vaccine was evaluated in healthy adults and RSV-seropositive children aged 12-24 months. The study, conducted in part at AMR Clinical locations, found the vaccine to be well tolerated in both age groups. Among children, neutralizing antibody titers rose sharply post-vaccination and remained elevated for months. Fewer RSV infections were reported in vaccine recipients vs. placebo over the study period.
Read this publication to explore:
- Immunogenicity outcomes in toddlers and adults
- Safety and tolerability across age and dose groups
- Preliminary data on RSV infection rates post-vaccination